Twitter Beğeni Hilesi

Over 1000 rebounds😳 to God be the glory🙏🏽💙

You forgot #ChiefsKingdom

What a great update of the 2023 metastatic non-oncogene addicted NSCLC ESMO - Eur. Oncology guideline. A pleasure to participate under the coordination of Lizza Hendriks and Martin Reck and with all experts Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Solange Peters Tony Mok Ben Solomon Jessica Menis Egbert Smit …

Really looking forward to this program with James Davis, PharmD, BCOP and Sara Moran Smith. Come join the discussion on how institutions across the country are working to incorporate bispecific antibodies safely & effectively into their practice!

#Lungcancer deaths from radon exposure are preventable if more people take action to reduce radon levels in homes, building, and schools. Raising awareness about radon saves lives. Spread the word for #RadonAwarenessWeek bit.ly/3Viw5mr #LCSM

Are you ready to ride? 😎 Our Talking Glossary of Genomic and Genetic Terms helps you learn about everything from the basics of genomics to the latest sequencing technology in a fun and easy way. Hop on: genome.gov/genetics-gloss…

Review from my colleagues in NatureRevClinOncol on the less common variants of NSCLC. Key reminder that these diseases, like MET exon 14 or ALK+ lung cancer have similar incidence to some leukemias or lymphomas nature.com/articles/s4157… Alexander Drilon MD Guilherme Harada

What is happening? Did someone wake up today and decide to just release tons of new trial results? Hard to keep up!

Thoracic oncologists trying to get some work done this week with all these exciting press releases swirling

Pharmacists are ideally positioned to lead institutional molecular tumor boards, according to the leaders of a growing certification program in oncology genomics from the ACCP. pharmacypracticenews.com/Clinical/Artic… University of Kentucky College of Pharmacy Markey Cancer Center Moffitt Cancer Center Todd Knepper @HeidiDiann Jason Bergsbaken, PharmD, MBA, BCOP UW Health

Come listen to how new data is changing the treatment algorithm for early stage NSCLC in Austin this weekend!

✋ questions for your medical oncologist 1. What type of cancer do I have? 2. Where is the cancer in my body? 3. What are my treatment goals? 4. Who is on my care team? 5. What are next steps for treatment? fal.cn/3zrPz Thanks to MD Anderson Cancer Center for the interview!

Join us in congratulating to our very own Daniel Hausrath on his wedding day! Wishing you both a lifetime of happiness! ❤️

Simultaneous NEJM publication of DeLLphi-301 study after #ESMO23 presentation by Dr. Luis Paz-Ares. This DLL3 bispecific shows tremendous promise in previously treated #SCLC and represents an exciting new strategy for this disease. nejm.org/doi/full/10.10…

ATTLAS study presented by Myung-Ju Ahn - EGFR+ post TKI pem-pt vs Atezo-Bev-Carbo-Tax. Better PFS for ABCP, same OS at this point

So proud of how it turned out!!

Are we heading toward a future where #lungcancer is NOT the leading cause of US cancer mortality in either men or women? Data out today in doi.org/10.3322/caac.2… continuing a nice trend --

🌟 NSCLC Drug List 🫁🧬 A month late, but I have compiled a list of NSCLC drugs for 2024. Approved and unapproved are excluded. References are as follows. NCCN Ver 1. 2024 ESMO Guideline JLCS Guideline 2023

Dr. Lizza Hendriks et al in #JTOCRR shows osimertinib plasma concentration not linked to CNS control. Prospective analysis of pts w/ #EGFR NSCLC showed osimertinib plasma trough levels not linked to risk of CNS progression or developing new brain mets. jtocrr.org/article/S2666-…

Great Vanderbilt-Ingram Cancer Center Grand Rounds presentation today from Ronak H. Mistry, DO !!!